Mar 12, 2019 / 02:45PM GMT
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst
Okay. Welcome to the morning session of the Barclays Global Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst, and have Jason Zemansky here from my team on the podium.
We're thrilled to have Gilead Sciences here. And we have Robin Washington, CFO; and John McHutchison, Head of R&D and CSO.
Questions and Answers:
Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research AnalystI guess, we'll start with a few commercial questions, and then shift into the pipeline. So Robin, when you look at the Biktarvy launch in the U.S., it's been fantastic. You're new to brand and switch rates have been good. Maybe talk to what you guys view as the upside opportunity from here in the U.S. Is it just more of the same in the U.S.? And then, obviously, we can get into Europe, too.
Robin L. Washington - Gilead Sciences, Inc. - CFO & Executive VP